nivolumab,ipilimumab
bms
['breast', 'congrat', 'niche2']
congratulations dr #niche2 great study! immunotherapy for deficient mismatch repair colon cancer patients: major path response in 95%, &amp; pcr in 67% patients. superb applaud &amp; nice discussions by ( #breast oncologist ) &amp; james larkin #esmo22 
Professor: AUB Amer Univ Beirut; Head, Heme/Onc / Breast Ca; MD: ULB Bruxelles; Oncology SLRHC/Columbia U, NY; Tweets R my own/ Retweets do not mean endorsement